env 2-3
Vaccineexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00000746)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- env 2-3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000632 | Phase 1 | Nov 2, 1999 | Chiron, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000746 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000779 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000958 | Phase 1 | Nov 2, 1999 | Chiron, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000972 | Phase 1 | Nov 2, 1999 | Chiron, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 5 | 5 | 1 | 1999 |
| Chiron | For profit | 3 | 0 | 1 | 1999 |
2 organizations
Page 1 / 1